120 related articles for article (PubMed ID: 20636009)
21. Autoimmunity: basic mechanisms and implications in endocrine diseases. Part II.
Ballotti S; Chiarelli F; de Martino M
Horm Res; 2006; 66(3):142-52. PubMed ID: 16807509
[TBL] [Abstract][Full Text] [Related]
22. A key role for autoreactive B cells in the breakdown of T-cell tolerance to pyruvate dehydrogenase complex in the mouse.
Robe AJ; Kirby JA; Jones DE; Palmer JM
Hepatology; 2005 May; 41(5):1106-12. PubMed ID: 15830397
[TBL] [Abstract][Full Text] [Related]
23. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
[TBL] [Abstract][Full Text] [Related]
24. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
Jasani B; Navabi H; Adams M
Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
[TBL] [Abstract][Full Text] [Related]
25. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells.
Chen G
Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):27-36. PubMed ID: 20049648
[TBL] [Abstract][Full Text] [Related]
27. Biotherapies targeting T and B cells: from immune suppression to immune tolerance.
Chatenoud L
Curr Opin Pharmacol; 2015 Aug; 23():92-7. PubMed ID: 26099946
[TBL] [Abstract][Full Text] [Related]
28. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
29. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
30. B lymphocytes are required for development and treatment of autoimmune diseases.
Youinou P; Jamin C; Pers JO; Berthou C; Saraux A; Renaudineau Y
Ann N Y Acad Sci; 2005 Jun; 1050():19-33. PubMed ID: 16014517
[TBL] [Abstract][Full Text] [Related]
31. Regulation of autoreactive antibodies.
Yurasov S; Nussenzweig MC
Curr Opin Rheumatol; 2007 Sep; 19(5):421-6. PubMed ID: 17762605
[TBL] [Abstract][Full Text] [Related]
32. Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA.
Steinaa L; Rasmussen PB; Gautam A; Mouritsen S
Scand J Immunol; 2008 Feb; 67(2):113-20. PubMed ID: 18201366
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and spectrum of autoimmunity.
Perl A
Methods Mol Med; 2004; 102():1-8. PubMed ID: 15286377
[TBL] [Abstract][Full Text] [Related]
34. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
35. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
36. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
37. New understanding of immunological mechanisms.
Saalmüller A
Vet Microbiol; 2006 Oct; 117(1):32-8. PubMed ID: 16701965
[TBL] [Abstract][Full Text] [Related]
38. [Immune tolerance and active suppression in oncology. Immunological principles and therapeutic options].
Stremmel C; Klein P; Hohenberger W
Chirurg; 2002 Mar; 73(3):255-61. PubMed ID: 11963500
[TBL] [Abstract][Full Text] [Related]
39. Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance.
Nguyen TG; Little CB; Yenson VM; Jackson CJ; McCracken SA; Warning J; Stevens V; Gallery EG; Morris JM
J Autoimmun; 2010 Aug; 35(1):86-97. PubMed ID: 20456921
[TBL] [Abstract][Full Text] [Related]
40. DCs as targets for vaccine design.
Belz G; Smith C; Bharadwaj M; Rice A; Jackson D
Cytotherapy; 2004; 6(2):88-98. PubMed ID: 15203984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
